Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial
- PDF / 1,812,847 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 51 Downloads / 205 Views
ORIGINAL ARTICLE
Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial Akimitsu Miyauchi1 · Etsuro Hamaya2 · Wenjing Yang3 · Kiyoshi Nishi2 · Cesar Libanati4 · Cae Tolman5 · Junichiro Shimauchi2 Received: 30 June 2020 / Accepted: 20 August 2020 © The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2020
Abstract Introduction This post-hoc analysis of the FRAME study investigated the long-term efficacy and safety of romosozumab followed by denosumab in postmenopausal Japanese women with osteoporosis at high fracture risk. Materials and methods Data from Japanese women with a high fracture risk participating in the international, randomised, double-blind, placebo-controlled, phase 3 FRAME study were analysed. High risk of fracture was defined as ≥ 1 fragility fracture with bone mineral density (BMD) ≤ − 2.5 standard deviations [SD], > 2 prevalent vertebral fractures, prevalent semiquantitative grade 3 vertebral fracture, or lumbar spine BMD
Data Loading...
